[go: up one dir, main page]

ATE517893T1 - Arylvinylazacycloalkan-verbindungen sowie herstellungsverfahren dafür und verwendung davon - Google Patents

Arylvinylazacycloalkan-verbindungen sowie herstellungsverfahren dafür und verwendung davon

Info

Publication number
ATE517893T1
ATE517893T1 AT08075106T AT08075106T ATE517893T1 AT E517893 T1 ATE517893 T1 AT E517893T1 AT 08075106 T AT08075106 T AT 08075106T AT 08075106 T AT08075106 T AT 08075106T AT E517893 T1 ATE517893 T1 AT E517893T1
Authority
AT
Austria
Prior art keywords
arylvinylazacycloalkan
compounds
production process
production
arylvinylazacycloalkan compounds
Prior art date
Application number
AT08075106T
Other languages
English (en)
Inventor
Jeffrey Daniel Schmitt
Gary Maurice Dull
Arielle Genevois-Borella
Marc Capet
Michel Cheve
Craig Harrison Miller
Original Assignee
Targacept Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Targacept Inc filed Critical Targacept Inc
Application granted granted Critical
Publication of ATE517893T1 publication Critical patent/ATE517893T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12—Antidiarrhoeals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/34—Tobacco-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Addiction (AREA)
  • Epidemiology (AREA)
  • Virology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Psychology (AREA)
  • Immunology (AREA)
  • Oncology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Molecular Biology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • AIDS & HIV (AREA)
  • Hospice & Palliative Care (AREA)
  • Rheumatology (AREA)
  • Communicable Diseases (AREA)
  • Anesthesiology (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
AT08075106T 2003-03-05 2004-03-04 Arylvinylazacycloalkan-verbindungen sowie herstellungsverfahren dafür und verwendung davon ATE517893T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US10/379,868 US7098331B2 (en) 2003-03-05 2003-03-05 Arylvinylazacycloalkane compounds and methods of preparation and use thereof

Publications (1)

Publication Number Publication Date
ATE517893T1 true ATE517893T1 (de) 2011-08-15

Family

ID=32926772

Family Applications (3)

Application Number Title Priority Date Filing Date
AT08075106T ATE517893T1 (de) 2003-03-05 2004-03-04 Arylvinylazacycloalkan-verbindungen sowie herstellungsverfahren dafür und verwendung davon
AT09075124T ATE496046T1 (de) 2003-03-05 2004-03-04 Arylvinylazacycloalkan-verbindungen und verfahren zu deren herstellung und verwendung
AT04717398T ATE394394T1 (de) 2003-03-05 2004-03-04 Arylvinylazacycloalkane verbindungen und methoden zu ihrer herstellung und deren verwendung

Family Applications After (2)

Application Number Title Priority Date Filing Date
AT09075124T ATE496046T1 (de) 2003-03-05 2004-03-04 Arylvinylazacycloalkan-verbindungen und verfahren zu deren herstellung und verwendung
AT04717398T ATE394394T1 (de) 2003-03-05 2004-03-04 Arylvinylazacycloalkane verbindungen und methoden zu ihrer herstellung und deren verwendung

Country Status (32)

Country Link
US (8) US7098331B2 (de)
EP (3) EP1601670B1 (de)
JP (3) JP4663627B2 (de)
KR (4) KR20120014236A (de)
CN (3) CN101550132B (de)
AR (3) AR043469A1 (de)
AT (3) ATE517893T1 (de)
AU (3) AU2004217903B2 (de)
BR (1) BRPI0409576A (de)
CA (1) CA2516514C (de)
CL (1) CL2004000452A1 (de)
CY (2) CY1110391T1 (de)
DE (2) DE602004031165D1 (de)
DK (2) DK1601670T3 (de)
EA (3) EA010870B1 (de)
ES (3) ES2389106T3 (de)
GT (1) GT200400033A (de)
HK (3) HK1084949A1 (de)
IL (3) IL170155A (de)
JO (1) JO2488B1 (de)
MX (1) MXPA05009386A (de)
NO (3) NO331920B1 (de)
NZ (1) NZ541795A (de)
PA (1) PA8597201A1 (de)
PE (1) PE20040930A1 (de)
PL (5) PL216979B1 (de)
PT (2) PT1601670E (de)
SI (2) SI1601670T1 (de)
TW (3) TWI377204B (de)
UY (1) UY28218A1 (de)
WO (1) WO2004078752A1 (de)
ZA (1) ZA200506790B (de)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7098331B2 (en) * 2003-03-05 2006-08-29 Targacept, Inc. Arylvinylazacycloalkane compounds and methods of preparation and use thereof
FR2896800B1 (fr) 2006-01-30 2008-04-11 Servier Lab Nouveaux composes pyridinylaminoalkylene-et pyridinyloxyalkylene-cyclopropanamines polysubstitues, leur procede de preparation et les compositions pharmaceutiques qui les contiennent.
WO2008157365A2 (en) * 2007-06-15 2008-12-24 Targacept, Inc. Vinylazacycloalkanes for treating neuropathic pain
EP2647373A1 (de) * 2008-05-12 2013-10-09 Targacept, Inc. Verfahren zur Prävention der Entwicklung von Retinopathie durch orale Verabreichung von Exo-S-Mecamylamine
TW201024283A (en) * 2008-12-01 2010-07-01 Targacept Inc Synthesis and novel salt forms of (R)-3-((E)-2-(pyrrolidin-3-yl)vinyl)-5-(tetrahydropyran-4-yloxy)pyridine
US9145396B2 (en) 2008-12-01 2015-09-29 Targacept, Inc. Synthesis and novel salt forms of (R)-5-((E)-2-pyrrolidin-3ylvinyl)pyrimidine
NZ611965A (en) * 2008-12-01 2015-01-30 Targacept Inc Synthesis and novel salt forms of (r)-5-((e)-2-(pyrrolidin-3-ylvinyl)pyrimidine
WO2010080757A2 (en) 2009-01-07 2010-07-15 Astrazeneca Ab Combinations with an alpha-4beta-2 nicotinic agonist
MX2011013860A (es) * 2009-06-17 2012-01-30 Targacept Inc Inversion de la discinesia inducida por levopoda mediante los ligandos del receptor nicotinico neural.
AU2010328419A1 (en) 2009-12-07 2012-06-21 Targacept, Inc. 3,6-diazabicyclo[3.1.1]heptanes as neuronal nicotinic acetylcholine receptor ligands
CA2792157A1 (en) * 2010-03-11 2011-09-15 Targacept, Inc. Arylvinylazacycloalkane compounds for constipation
US20110274628A1 (en) * 2010-05-07 2011-11-10 Borschke August J Nicotine-containing pharmaceutical compositions
US20140081714A1 (en) * 2012-09-19 2014-03-20 Salesforce.Com, Inc. Systems and methods of rewarding users in an on-demand system
US20140278929A1 (en) * 2013-03-15 2014-09-18 Yahoo! Inc. System and method identifying opportunities for advertising entities based on user goal achievement
EA201892265A1 (ru) 2016-04-07 2019-04-30 Ойстер Поинт Фарма, Инк. Способы лечения офтальмологических заболеваний
KR101848601B1 (ko) * 2016-07-27 2018-04-12 송기봉 일회용 위생 티슈
TW202019424A (zh) 2018-07-10 2020-06-01 美商奧伊斯特普安生物製藥公司 治療眼部症狀之方法
CN112638364A (zh) 2018-07-10 2021-04-09 奥伊斯特普安生物制药公司 用于治疗眼部病症的正向别构调节剂和烟碱型乙酰胆碱受体激动剂的组合
TW202206078A (zh) 2020-04-28 2022-02-16 美商奧伊斯特普安生物製藥公司 局部投與菸鹼乙醯膽鹼受體促效劑用以抑制冠狀病毒感染

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1989000158A1 (en) 1987-07-02 1989-01-12 Pfizer Inc. Bridged-diazabicycloalkyl quinolone carboxylic acids and esters
US4922901A (en) 1988-09-08 1990-05-08 R. J. Reynolds Tobacco Company Drug delivery articles utilizing electrical energy
US5187166A (en) 1990-07-31 1993-02-16 Nisshin Flour Milling Co., Ltd. Azabicyclo derivatives and their use as antiemetics
IL107184A (en) 1992-10-09 1997-08-14 Abbott Lab Heterocyclic ether compounds that enhance cognitive function
US5852041A (en) 1993-04-07 1998-12-22 Sibia Neurosciences, Inc. Substituted pyridines useful as modulators of acethylcholine receptors
IT1274018B (it) 1994-02-23 1997-07-14 Riace Ets Derivati del 3,8-diazabiciclo(3.2.1.)ottano ad attivita' analgesica
GB2295387A (en) 1994-11-23 1996-05-29 Glaxo Inc Quinazoline antagonists of alpha 1c adrenergic receptors
US5604231A (en) 1995-01-06 1997-02-18 Smith; Carr J. Pharmaceutical compositions for prevention and treatment of ulcerative colitis
US5597919A (en) 1995-01-06 1997-01-28 Dull; Gary M. Pyrimidinyl or Pyridinyl alkenyl amine compounds
US5585388A (en) 1995-04-07 1996-12-17 Sibia Neurosciences, Inc. Substituted pyridines useful as modulators of acetylcholine receptors
US5583140A (en) 1995-05-17 1996-12-10 Bencherif; Merouane Pharmaceutical compositions for the treatment of central nervous system disorders
IL118279A (en) 1995-06-07 2006-10-05 Abbott Lab Compounds 3 - Pyridyloxy (or Thio) Alkyl Heterocyclic Pharmaceutical Compositions Containing Them and Their Uses for Preparing Drugs to Control Synaptic Chemical Transmission
US5616716A (en) 1996-01-06 1997-04-01 Dull; Gary M. (3-(5-ethoxypyridin)yl)-alkenyl 1 amine compounds
AT403803B (de) 1996-04-19 1998-05-25 Sanochemia Ltd Neue benzazepinderivate, diese enthaltende arzneimittel und verwendung derselben zum herstellen von arzneimitteln
US5663356A (en) 1996-04-23 1997-09-02 Ruecroft; Graham Method for preparation of aryl substituted alefinic secondary amino compounds
US6437138B1 (en) 1996-06-06 2002-08-20 Abbott Laboratories 3-pyridyloxymethyl heterocyclic ether compounds useful in controlling chemical synaptic transmission
US5629325A (en) 1996-06-06 1997-05-13 Abbott Laboratories 3-pyridyloxymethyl heterocyclic ether compounds useful in controlling chemical synaptic transmission
EP1491532B1 (de) 1997-10-27 2010-12-15 NeuroSearch A/S Heteroaryl Diazacycloalkane als cholinergische Ligande für Nikotin-Acetylcholin-Rezeptoren
WO2000075110A1 (en) 1999-06-07 2000-12-14 Targacept, Inc. Pharmaceutical compositions and methods for use
EP1212319A2 (de) 1999-09-14 2002-06-12 Abbott Laboratories 3-pyrrolidinyloxy-3' -pyridyl ether verbindungen verwendbar zur steuerung von chemischer synaptischer übertragung
JP2003513054A (ja) 1999-11-01 2003-04-08 ターガセプト，インコーポレイテッド アリールオレフィンアザ環式化合物及びアリールアセチレンアザ環式化合物、それらを含有する薬剤組成物、及び、ニコチンコリン作動性受容体の阻害薬としてのそれらの使用
US6624167B1 (en) * 2000-08-04 2003-09-23 Targacept, Inc. Pharmaceutical compositions and methods for use
AU2002322562A1 (en) 2001-07-19 2003-03-03 Medical College Of Georgia Research Institute Novel analogs of choline for neuroprotection and cognitive enhancement in neurodegenerative disorders
US7098331B2 (en) 2003-03-05 2006-08-29 Targacept, Inc. Arylvinylazacycloalkane compounds and methods of preparation and use thereof

Also Published As

Publication number Publication date
AU2008258187A1 (en) 2009-01-15
TWI339662B (en) 2011-04-01
ES2385941T3 (es) 2012-08-03
CN100526308C (zh) 2009-08-12
PL215059B1 (pl) 2013-10-31
US8633222B2 (en) 2014-01-21
ATE496046T1 (de) 2011-02-15
NZ541795A (en) 2008-03-28
JO2488B1 (en) 2009-10-05
PA8597201A1 (es) 2004-09-28
SI1601670T1 (sl) 2008-10-31
NO331920B1 (no) 2012-04-30
EP1601670A1 (de) 2005-12-07
CY1111615T1 (el) 2015-10-07
PL216979B1 (pl) 2014-06-30
EP1947100A1 (de) 2008-07-23
KR20090021228A (ko) 2009-02-27
PL378415A1 (pl) 2006-04-03
EP1947100B1 (de) 2011-07-27
CA2516514C (en) 2012-02-07
AR070570A2 (es) 2010-04-21
AU2004217903A1 (en) 2004-09-16
BRPI0409576A (pt) 2006-04-18
US20040176348A1 (en) 2004-09-09
NO20054120D0 (no) 2005-09-05
US20100010042A1 (en) 2010-01-14
JP5537085B2 (ja) 2014-07-02
AU2008258187B2 (en) 2010-08-05
TWI377204B (en) 2012-11-21
EP2085395A1 (de) 2009-08-05
NO20054120L (no) 2005-10-03
GT200400033A (es) 2005-05-29
ES2309507T3 (es) 2008-12-16
DE602004013553D1 (de) 2008-06-19
HK1130254A1 (en) 2009-12-24
PL394604A1 (pl) 2011-07-18
CN101550132A (zh) 2009-10-07
TW200505909A (en) 2005-02-16
CA2516514A1 (en) 2004-09-16
CN101255155A (zh) 2008-09-03
ZA200506790B (en) 2006-05-31
ATE394394T1 (de) 2008-05-15
PL1601670T3 (pl) 2008-10-31
JP2010001296A (ja) 2010-01-07
MXPA05009386A (es) 2005-11-04
UY28218A1 (es) 2005-06-30
CN1756754A (zh) 2006-04-05
US20100267776A1 (en) 2010-10-21
AR043469A1 (es) 2005-07-27
PT2085395E (pt) 2011-04-20
KR101018083B1 (ko) 2011-03-02
PT1601670E (pt) 2008-07-11
JP2009292825A (ja) 2009-12-17
KR20120014236A (ko) 2012-02-16
EP1601670B1 (de) 2008-05-07
IL197889A (en) 2013-03-24
PL2085395T3 (pl) 2011-05-31
NO20092231L (no) 2005-10-03
NO20091888L (no) 2005-10-03
NO332293B1 (no) 2012-08-20
TW200927745A (en) 2009-07-01
KR20060006006A (ko) 2006-01-18
EA200801764A1 (ru) 2008-12-30
AU2008258188B2 (en) 2011-02-24
EP2085395B1 (de) 2011-01-19
US20140107164A1 (en) 2014-04-17
AU2004217903B2 (en) 2010-03-04
EA019240B1 (ru) 2014-02-28
US20080293778A1 (en) 2008-11-27
US8063068B2 (en) 2011-11-22
US20110152293A1 (en) 2011-06-23
KR101185541B1 (ko) 2012-09-24
KR100953150B1 (ko) 2010-04-19
PL394600A1 (pl) 2011-07-18
AR070569A2 (es) 2010-04-21
CY1110391T1 (el) 2015-04-29
US7714001B2 (en) 2010-05-11
JP4663627B2 (ja) 2011-04-06
IL197890A (en) 2013-11-28
CL2004000452A1 (es) 2005-05-20
PE20040930A1 (es) 2005-02-18
JP2006519868A (ja) 2006-08-31
US20060094732A1 (en) 2006-05-04
SI2085395T1 (sl) 2011-05-31
HK1084949A1 (en) 2006-08-11
DK1601670T3 (da) 2008-08-25
EA014714B1 (ru) 2011-02-28
CN101550132B (zh) 2012-03-28
US8067443B2 (en) 2011-11-29
EA010870B1 (ru) 2008-12-30
KR20090021227A (ko) 2009-02-27
WO2004078752A1 (en) 2004-09-16
IL170155A (en) 2013-08-29
TW200927746A (en) 2009-07-01
HK1116800A1 (en) 2009-01-02
US20150164894A1 (en) 2015-06-18
JP5537084B2 (ja) 2014-07-02
EA200501425A1 (ru) 2006-02-24
DE602004031165D1 (de) 2011-03-03
ES2389106T3 (es) 2012-10-23
DK2085395T3 (da) 2011-04-18
US7098331B2 (en) 2006-08-29
EA200900706A1 (ru) 2009-10-30
AU2008258188A1 (en) 2009-01-15

Similar Documents

Publication Publication Date Title
DE60324888D1 (de) und Herstellungsverfahren
ATE517893T1 (de) Arylvinylazacycloalkan-verbindungen sowie herstellungsverfahren dafür und verwendung davon
DE60319810D1 (de) Anschwemmfiltermedien und herstellungs- und verwendungsverfahren
CY2015015I1 (el) Παραγωγη τιακουμυκινης
ATE415966T1 (de) Substituierte 3-amino-thieno(2,3-b)pyridine-2- amide und herstellungsverfahren sowie deren verwendung
DE60225385D1 (de) Autentisches Document und dessen Herstellungsverfahren
DE60310339D1 (de) Querträger und Herstellungsverfahren
EP1855882A4 (de) Neue markierungen und herstellungsverfahren dafür
DE602004019377D1 (de) Reifenherstellungseinheit und Reifenherstellungsverfahren
DE602004017600D1 (de) Abbildungseinrichtung und herstellungsverfahren dafür
NO20053796D0 (no) Process for the production of particles
DE602004018896D1 (de) Duplexer und Herstellungsverfahen
ATE448295T1 (de) Künstliche dermis und herstellungsverfahren dafür
DE60211082D1 (de) Toner und Tonerherstellungsverfahren
DE602004032341D1 (de) Kieselsäure enthaltende kautschukzusammensetzung und herstellungsverfahren dafür
EP1731528A4 (de) Verfahren zur herstellung von solubilisiertem keratin
IS8491A (is) Nýtt efnasamband, samsvarandi blöndur, framleiðslu- og/eða meðhöndlunaraðferðir
PL1608811T3 (pl) Wyrób wielowarstwowy i sposób jego wytwarzania
DE60211579D1 (de) Filter und dessen Herstellungverfahren
DE602004007566D1 (de) Pressform und Herstellmethode derselben
DE60328482D1 (de) Strahlungsfilterelement und herstellungsprozess dafür
DE60306074D1 (de) Mikrokapsel sowie Herstellungsverfahren
DE60315169D1 (de) Optisches mikrosystem und herstellungsverfahren
DE602004006815D1 (de) Monolithischer Halbleiterlaser und dessen Herstellungsverfahren
DE602004013124D1 (de) Schleifverfahren

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties